Dosing & Administration

Considerations for Use

Considerations when deciding if RADICAVA® (edaravone) is appropriate for your patients1:

  • Indicated for the treatment of amyotrophic lateral sclerosis (ALS)
  • May be received concomitantly with riluzole
  • No known drug interactionsa (see full Prescribing Information)

To learn how to order RADICAVA®, go here.

When ordering RADICAVA®, advise patients to read the Patient Information for RADICAVA®, and to tell you1,2:

  • If they have asthma
  • If they are allergic to other medicines
  • If they are pregnant or intend to become pregnant
  • If they are breastfeeding or intend to breastfeed
  • About all the of the medicines they are taking

aBased on in vitro drug interaction studies. For more details, see the full Prescribing Information.

HCP with couple HCP with couple

Administering RADICAVA®

RADICAVA® is an intravenous (IV) medication for the treatment of ALS.1 It should be administered under the guidance of a healthcare provider (HCP). RADICAVA® may be administered at an infusion center, a doctor's office, a hospital, or at home. Patients should consult their HCP and insurance plan to determine which option is right for them.

IV infusion

IV infusion
(60 mg)1

two 30-mg bags

Two 30 mg

60 mins to receive full dose

60 minutes to
receive full dose1

How to administer1

Administer each 60 mg dose of RADICAVA® as 2 consecutive 30 mg IV infusion bags over a total of 60 minutes (infusion rate ~1 mg per minute)

  • Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction
  • Other medications should not be injected into infusion bag or mixed with RADICAVA®
  • Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue RADICAVA®, treat per standard of care, and monitor until the condition resolves
  • Advise patients to seek immediate medical care if they experience signs or symptoms of a hypersensitivity reaction or a sulfite allergic reaction

How to infuse RADICAVA®

Watch a brief video that explains how to administer and store RADICAVA®. See full Prescribing Information for complete dosing and administration information.

Preparing the infusion bag

Follow these instructions to help prevent damage to the stopper and avoid leakage of medication.

You can also download these instructions.

Step 1: Align Spike

Handle the bag gently. Hold the bag with the rubber stopper facing upward. If the bag is already hanging, remove it from the IV pole. Align the spike to the center of the stopper without twisting. DO NOT spike upward. It is important NOT to insert the spike at an angle.

Step 2: Carefully Insert Spike

Very gently and carefully insert the spike straight into the center of the stopper. It is important not to twist the spike when inserting it into the IV bag.

Be sure to only spike once. DO NOT spike multiple times.

Avoid Damage to the Stopper

Be careful NOT to insert the spike at an angle. Doing so may damage the IV bag and cause medication leakage.


Infusion schedule

RADICAVA® is an ongoing treatment for ALS. For the first cycle, RADICAVA® is infused for 14 days, followed by a 14-day drug-free period. Subsequent cycles are infused for 10 days within a 14-day period, followed by a 14-day drug-free period.1

Our Care Coordinators at Searchlight Support® can help patients find an infusion site of care. To learn more, call 1-844-SRCHLGT (1-844-772-4548) or go here.

Modes of Infusion

RADICAVA® may be administered via a central or peripheral IV device. To learn more, you can download information about these modes of infusion.

References: 1. RADICAVA Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2018. 2. RADICAVA Patient Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2018.

Important Safety Information

Hypersensitivity Reactions

Radicava® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.


Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or


Radicava® is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Please see full Prescribing Information.

For more information about RADICAVA®, call 1-888-292-0058.